Skip to main content
SpringerLink
Log in

Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Sarpogrelate, a specific 5-HT2A receptor antagonist is reported to produce a number of beneficial cardiovascular effects in diabetes mellitus. In the present investigation we have studied the effects of sarpogrelate on 5-HT receptors in heart and platelets in streptozotocin (STZ)-diabetic rats. Diabetes was induced by a single tail vein injection of STZ (45 mg/kg) and sarpogrelate (1 mg/kg, i.p.) was administered daily for 6 weeks. Injection of STZ produced significant loss of body weight, polyphagia, polydypsia, hyperglycemia, hypoinsulinemia, hypertension and bradycardia. Treatment with sarpogrelate significantly lowered fasting glucose levels with corresponding increase in insulin levels. It also significantly prevented STZ-induced polydypsia, hyperphagia, hypertension, and bradycardia but not the loss of body weight. 5-HT produced dose-dependent positive inotropic effect that was found to be decreased significantly in STZ-diabetic rats. Hearts obtained from sarpogrelate treated diabetic rats did not show any decrease in responsiveness to 5-HT. Relative platelet aggregation per se was found to be higher in STZ-diabetic rats as compared to control and this was significantly prevented by sarpogrelate treatment. 5-HT produced a dose-dependent increase in platelet aggregation in non-diabetic and sarpogrelate treated diabetic rats. However, 5-HT failed to produce any increase in platelet aggregation in untreated diabetic rats. Our data suggest that STZ-induced diabetes may produce down-regulation of cardiac 5-HT2A receptors and increased platelet aggregation. Treatment with sarpogrelate seems to prevent STZ-induced down-regulation of 5-HT receptors and increase in platelet activity in diabetic rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McCall RB, Clement ME: Role of serotonin1A and serotonin2 receptors in the central regulation of the cardiovascular system. Pharm Rev 46: 231-243, 1994

    Google Scholar 

  2. Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS: Inhibition of serotonin induced vascular muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther 290: 1475-1481, 1999

    Google Scholar 

  3. Hammamori Y, Yokoyama M, Yamada M, Akita H, Goshima K, Fukuzaki H: 5-Hydroxytryptamine induces phospholipase C mediated hydrolysis of phosphoinositides through 5-HT2 receptors in cultured fetal mouse ventricular myocytes. Circ Res 66: 1474-1483, 1990

    Google Scholar 

  4. Laer S, Remmers F, Scholz H, Stein B, Muller FU, Neumann J: Receptors mechanisms involved in the 5-HT induced inotropic action in the rat isolated atrium. Br J Pharmacol 123: 1182-1188, 1998

    Google Scholar 

  5. Page MM, Watkins PJ: The heart in diabetes: Autonomic neuropathy and cardiomyopathy. Clin Endocrinol Metab 6: 377-388, 1977

    Google Scholar 

  6. Dhalla NS, Pierce GN, Innes IR, Beamish RE: Pathogenesis of cardiac dysfunction in diabetes mellitus. Can J Cardiol 1: 263-281, 1985

    Google Scholar 

  7. Latifpour, McNeill JH: Cardiac autonomic receptors: Effects of long term experimental diabetes. J Pharmacol Exp Ther 230: 242-249, 1984

    Google Scholar 

  8. Hagen AA, Shirasawa Y, White RP: Experimental diabetes: Reduction of serotonin-induced vasoconstriction by meclofenamic acid in vitro Pharmacology 30: 197-204, 1985

    Google Scholar 

  9. James GM, Hodgson WC, Davis EA, Haynes JM: Attenuated 5-hydroxytryptamine receptor mediated responses in aortae from STZ-induced diabetic rats. Br J Pharmacol 111: 370-375, 1994

    Google Scholar 

  10. Tobesseda X, Mealy N: Sarpogrelate hydrochloride: A peripheral serotonin 5-HT2 receptor antagonist with platelet anti aggregatory properties. Drugs Today 30: 43-48, 1994

    Google Scholar 

  11. Pietraszek MH, Takada Y, Taminato A, Yoshimi T, Watanabe I, Takada A: The effect of MCI-9042 on serotonin induced platelet aggregation in type 2 diabetes mellitus. Thromb Res 70: 131-138, 1993

    Google Scholar 

  12. Kwaan HC, Colwell JA, Cruz S: Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 20: 236, 1972

    Google Scholar 

  13. Nakanishi M, Imamura H, Ikegami K, Goto K: Pharmacological investigations of 2-amino-3-ethoxycarbonyl-6-benzyl-4,5,6,7-tetrahysdroethieno[2,3-o]pyridine. Arzneimittelforschung 20: 1004-1009, 1970

    Google Scholar 

  14. Gagliardino JJ, Zieher LM, Iturriza FC, Hernandez RE, Rodriguez RR: Insulin release and glucose changes induced by serotonin. Horm Metab Res 3: 145-150, 1971

    Google Scholar 

  15. Lechin F, Coll-Garcia E, Van Der Dijs B, Pena F, Bentolila A, Rivas C: The effect of serotonin (5-HT) on insulin secretion. Acta Physiol Lat Am 25: 339-346, 1975

    Google Scholar 

  16. Jacoby JH, Bryce GF: The acute pharmacological effects of serotonin on the release of insulin and glucagon in the intact rat. Arch Int Pharmacodyn Ther 235: 254-270, 1978

    Google Scholar 

  17. Botros M, Saba JA: The glycemic effects of serotonin (5-hydroxytryptamine). J Egypt Med Assoc 51: 41-47, 1968

    Google Scholar 

  18. Sugimoto Y, Yamada J, Yoshikawa T, Horisaka K: The effects of peripheral serotonin2 (5-HT2) and serotonin3 (5-HT3) receptor agonists on blood glucose levels in rats. Biol Pharm Bull 19: 1384-1386, 1996

    Google Scholar 

  19. Yamada J, Sugimoto Y, Yoshikawa T, Kimura I, Horisaka K: The involvement of the peripheral 5-HT2A receptor in peripherally administered serotonin-induced hyperglycemia in rats. Life Sci 57: 819-825, 1995

    Google Scholar 

  20. Ikeda K, Tojo K, Tokudome G, Hosoya T, Harada M, Nakao K: The effects of sarpogrelate on cardiomyocyte hypertrophy. Life Sci 67: 2991-2996, 2000

    Google Scholar 

  21. Hara H, Osakabe A, Kitajima Y, Kikumoto R: MCI-9042, a new anti-platelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 65: 415-420, 1991

    Google Scholar 

  22. Rydzewski A, Urano T, Hachiya T, Kanoko H, Baba S, Takada Y, Takada A: The effect of 5-HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res 84: 445-452, 1996

    Google Scholar 

  23. Furukawa K, Tanabe T, Hoshino S, Mishima Y, Shionoya S, Yoshizaki S: Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive diseases — a double-blind comparison with ticlopindine hydrochloride. J Clin Ther Med 7: 1747-1770, 1991

    Google Scholar 

  24. Nakamura K, Kariyazono H, Masuda H, Sakata R, Yamada: Effects of sarpogrelate hydrochloride on adenosine diphosphate-or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul Fibrinolysis 12: 391-397, 2001

    Google Scholar 

  25. Saxena PR: Cardiovascular effects from stimulation of 5-hydroxytryptamine receptors. Fund Clin Pharmacol 3: 245-265, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, India

    Dhananjay N. Umrani, Dipalo N. Bodiwala & Ramesh K. Goyal

Authors
  1. Dhananjay N. Umrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dipalo N. Bodiwala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramesh K. Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Umrani, D.N., Bodiwala, D.N. & Goyal, R.K. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats. Mol Cell Biochem 249, 53–57 (2003). https://doi.org/10.1023/A:1024762002836

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024762002836

Search

Navigation